Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT
Purpose To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC). Methods We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass–aortic peak hei...
Gespeichert in:
| Veröffentlicht in: | Clinical & translational oncology 2016-01, Vol.18 (1), p.47-57 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 57 |
|---|---|
| container_issue | 1 |
| container_start_page | 47 |
| container_title | Clinical & translational oncology |
| container_volume | 18 |
| creator | Qiao, P.-G. Zhang, H.-T. Zhou, J. Li, M. Ma, J.-L. Tian, N. Xing, X.-D. Li, G.-J. |
| description | Purpose
To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC).
Methods
We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass–aortic peak height ratio (M/A), and blood perfusion (BP) in 20 patients with advanced NSCLC using DCE-CT before and 7 days after treatment. Therapy efficacy was assessed with conventional CT 4–6 weeks post-treatment.
Results
Patients were grouped into those with partial response (PR), stable disease (SD), and progressive disease (PD) according to the therapy efficacy assessment at 4–6 weeks post-treatment. The PR group primary tumor diameter (
P
= 0.0007) and BP (
P
= 0.0225) were reduced at 7 days post-treatment; the SD group DCE-CT value changes were not significant. The PD group M/A (
P
= 0.0443) and BP (
P
= 0.0268) were increased 7 days post-treatment. The BP decrease group had significantly longer progression-free survival than the BP increase group (median, 54 vs. 6 weeks).
Conclusion
DCE-CT can evaluate targeted therapy efficacy at 7 days post-treatment. Decreased primary tumor diameter and BP indicate tumor sensitivity to therapy; increased BP with unchanged tumor diameter suggests the tumor is not sensitive to therapy. Reduced BP suggests treatment effectiveness. |
| doi_str_mv | 10.1007/s12094-015-1335-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760897727</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760897727</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-ca01f52ff986ecfc1b183add5a08036ef22cd23659116bef04fbe1e4a962014c3</originalsourceid><addsrcrecordid>eNp9kMtOxCAUhonReH8AN4alG5QDLW2XZuItMXGjiTtC6WGsaekI1GTeXiYzunQD5PyXHD5CLoBfA-fVTQTBm4JxKBlIWTK1R45BNQ2TvCz3d29e1O9H5CTGT56nCuCQHAklCikbeUxWdyYMa4rfZphN6idPJ0eTCUtM2NH0gcGssuwc2tR_o8cYae-pnzyLoxkGajEfw-yX1BpvMdB2Tbu1N2NvqZ18CiYmhv5jI3Z08XpGDpwZIp7v7lPydn_3unhkzy8PT4vbZ2YLKBKzhoMrhXNNrdA6Cy3U0nRdaXjNpUInhO2EVGUDoFp0vHAtAhamUYJDYeUpudr2rsL0NWNMeuzjZlnjcZqjhkrxuqkqUWUrbK02TDEGdHoV-tGEtQauN6D1FrTOoPUGtFY5c7mrn9sRu7_EL9lsEFtDzJJfYtCf0xx8_vI_rT8v5oqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760897727</pqid></control><display><type>article</type><title>Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><creator>Qiao, P.-G. ; Zhang, H.-T. ; Zhou, J. ; Li, M. ; Ma, J.-L. ; Tian, N. ; Xing, X.-D. ; Li, G.-J.</creator><creatorcontrib>Qiao, P.-G. ; Zhang, H.-T. ; Zhou, J. ; Li, M. ; Ma, J.-L. ; Tian, N. ; Xing, X.-D. ; Li, G.-J.</creatorcontrib><description>Purpose
To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC).
Methods
We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass–aortic peak height ratio (M/A), and blood perfusion (BP) in 20 patients with advanced NSCLC using DCE-CT before and 7 days after treatment. Therapy efficacy was assessed with conventional CT 4–6 weeks post-treatment.
Results
Patients were grouped into those with partial response (PR), stable disease (SD), and progressive disease (PD) according to the therapy efficacy assessment at 4–6 weeks post-treatment. The PR group primary tumor diameter (
P
= 0.0007) and BP (
P
= 0.0225) were reduced at 7 days post-treatment; the SD group DCE-CT value changes were not significant. The PD group M/A (
P
= 0.0443) and BP (
P
= 0.0268) were increased 7 days post-treatment. The BP decrease group had significantly longer progression-free survival than the BP increase group (median, 54 vs. 6 weeks).
Conclusion
DCE-CT can evaluate targeted therapy efficacy at 7 days post-treatment. Decreased primary tumor diameter and BP indicate tumor sensitivity to therapy; increased BP with unchanged tumor diameter suggests the tumor is not sensitive to therapy. Reduced BP suggests treatment effectiveness.</description><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-015-1335-6</identifier><identifier>PMID: 26243393</identifier><language>eng</language><publisher>Milan: Springer Milan</publisher><subject>Adult ; Aged ; Angiogenesis Inhibitors - therapeutic use ; Carcinoma, Non-Small-Cell Lung - diagnostic imaging ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Contrast Media ; Female ; Humans ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Molecular Targeted Therapy ; Oncology ; Prognosis ; Research Article ; Time Factors ; Tomography, Spiral Computed - methods ; Treatment Outcome</subject><ispartof>Clinical & translational oncology, 2016-01, Vol.18 (1), p.47-57</ispartof><rights>Federación de Sociedades Españolas de Oncología (FESEO) 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-ca01f52ff986ecfc1b183add5a08036ef22cd23659116bef04fbe1e4a962014c3</citedby><cites>FETCH-LOGICAL-c414t-ca01f52ff986ecfc1b183add5a08036ef22cd23659116bef04fbe1e4a962014c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12094-015-1335-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12094-015-1335-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26243393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qiao, P.-G.</creatorcontrib><creatorcontrib>Zhang, H.-T.</creatorcontrib><creatorcontrib>Zhou, J.</creatorcontrib><creatorcontrib>Li, M.</creatorcontrib><creatorcontrib>Ma, J.-L.</creatorcontrib><creatorcontrib>Tian, N.</creatorcontrib><creatorcontrib>Xing, X.-D.</creatorcontrib><creatorcontrib>Li, G.-J.</creatorcontrib><title>Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>Purpose
To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC).
Methods
We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass–aortic peak height ratio (M/A), and blood perfusion (BP) in 20 patients with advanced NSCLC using DCE-CT before and 7 days after treatment. Therapy efficacy was assessed with conventional CT 4–6 weeks post-treatment.
Results
Patients were grouped into those with partial response (PR), stable disease (SD), and progressive disease (PD) according to the therapy efficacy assessment at 4–6 weeks post-treatment. The PR group primary tumor diameter (
P
= 0.0007) and BP (
P
= 0.0225) were reduced at 7 days post-treatment; the SD group DCE-CT value changes were not significant. The PD group M/A (
P
= 0.0443) and BP (
P
= 0.0268) were increased 7 days post-treatment. The BP decrease group had significantly longer progression-free survival than the BP increase group (median, 54 vs. 6 weeks).
Conclusion
DCE-CT can evaluate targeted therapy efficacy at 7 days post-treatment. Decreased primary tumor diameter and BP indicate tumor sensitivity to therapy; increased BP with unchanged tumor diameter suggests the tumor is not sensitive to therapy. Reduced BP suggests treatment effectiveness.</description><subject>Adult</subject><subject>Aged</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Contrast Media</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Molecular Targeted Therapy</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Research Article</subject><subject>Time Factors</subject><subject>Tomography, Spiral Computed - methods</subject><subject>Treatment Outcome</subject><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOxCAUhonReH8AN4alG5QDLW2XZuItMXGjiTtC6WGsaekI1GTeXiYzunQD5PyXHD5CLoBfA-fVTQTBm4JxKBlIWTK1R45BNQ2TvCz3d29e1O9H5CTGT56nCuCQHAklCikbeUxWdyYMa4rfZphN6idPJ0eTCUtM2NH0gcGssuwc2tR_o8cYae-pnzyLoxkGajEfw-yX1BpvMdB2Tbu1N2NvqZ18CiYmhv5jI3Z08XpGDpwZIp7v7lPydn_3unhkzy8PT4vbZ2YLKBKzhoMrhXNNrdA6Cy3U0nRdaXjNpUInhO2EVGUDoFp0vHAtAhamUYJDYeUpudr2rsL0NWNMeuzjZlnjcZqjhkrxuqkqUWUrbK02TDEGdHoV-tGEtQauN6D1FrTOoPUGtFY5c7mrn9sRu7_EL9lsEFtDzJJfYtCf0xx8_vI_rT8v5oqA</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Qiao, P.-G.</creator><creator>Zhang, H.-T.</creator><creator>Zhou, J.</creator><creator>Li, M.</creator><creator>Ma, J.-L.</creator><creator>Tian, N.</creator><creator>Xing, X.-D.</creator><creator>Li, G.-J.</creator><general>Springer Milan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT</title><author>Qiao, P.-G. ; Zhang, H.-T. ; Zhou, J. ; Li, M. ; Ma, J.-L. ; Tian, N. ; Xing, X.-D. ; Li, G.-J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-ca01f52ff986ecfc1b183add5a08036ef22cd23659116bef04fbe1e4a962014c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnostic imaging</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Contrast Media</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Molecular Targeted Therapy</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Research Article</topic><topic>Time Factors</topic><topic>Tomography, Spiral Computed - methods</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qiao, P.-G.</creatorcontrib><creatorcontrib>Zhang, H.-T.</creatorcontrib><creatorcontrib>Zhou, J.</creatorcontrib><creatorcontrib>Li, M.</creatorcontrib><creatorcontrib>Ma, J.-L.</creatorcontrib><creatorcontrib>Tian, N.</creatorcontrib><creatorcontrib>Xing, X.-D.</creatorcontrib><creatorcontrib>Li, G.-J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qiao, P.-G.</au><au>Zhang, H.-T.</au><au>Zhou, J.</au><au>Li, M.</au><au>Ma, J.-L.</au><au>Tian, N.</au><au>Xing, X.-D.</au><au>Li, G.-J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT</atitle><jtitle>Clinical & translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>18</volume><issue>1</issue><spage>47</spage><epage>57</epage><pages>47-57</pages><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>Purpose
To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC).
Methods
We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass–aortic peak height ratio (M/A), and blood perfusion (BP) in 20 patients with advanced NSCLC using DCE-CT before and 7 days after treatment. Therapy efficacy was assessed with conventional CT 4–6 weeks post-treatment.
Results
Patients were grouped into those with partial response (PR), stable disease (SD), and progressive disease (PD) according to the therapy efficacy assessment at 4–6 weeks post-treatment. The PR group primary tumor diameter (
P
= 0.0007) and BP (
P
= 0.0225) were reduced at 7 days post-treatment; the SD group DCE-CT value changes were not significant. The PD group M/A (
P
= 0.0443) and BP (
P
= 0.0268) were increased 7 days post-treatment. The BP decrease group had significantly longer progression-free survival than the BP increase group (median, 54 vs. 6 weeks).
Conclusion
DCE-CT can evaluate targeted therapy efficacy at 7 days post-treatment. Decreased primary tumor diameter and BP indicate tumor sensitivity to therapy; increased BP with unchanged tumor diameter suggests the tumor is not sensitive to therapy. Reduced BP suggests treatment effectiveness.</abstract><cop>Milan</cop><pub>Springer Milan</pub><pmid>26243393</pmid><doi>10.1007/s12094-015-1335-6</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2016-01, Vol.18 (1), p.47-57 |
| issn | 1699-048X 1699-3055 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760897727 |
| source | MEDLINE; SpringerNature Complete Journals |
| subjects | Adult Aged Angiogenesis Inhibitors - therapeutic use Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Contrast Media Female Humans Lung Neoplasms - diagnostic imaging Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Molecular Targeted Therapy Oncology Prognosis Research Article Time Factors Tomography, Spiral Computed - methods Treatment Outcome |
| title | Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A56%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20evaluation%20of%20targeted%20therapy%20effectiveness%20in%20non-small%20cell%20lung%20cancer%20by%20dynamic%20contrast-enhanced%20CT&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Qiao,%20P.-G.&rft.date=2016-01-01&rft.volume=18&rft.issue=1&rft.spage=47&rft.epage=57&rft.pages=47-57&rft.issn=1699-048X&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-015-1335-6&rft_dat=%3Cproquest_cross%3E1760897727%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760897727&rft_id=info:pmid/26243393&rfr_iscdi=true |